Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequencing Sacituzumab Govitecan after T-DXd in ER+/HER2-low MBC
NCT06665178Phase 2Recruiting
- Sponsor
- BC Cancer
- Start
- Mar 2025
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab govitecan in breast cancer, sponsored by BC Cancer. Started Mar 2025; status: recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06665178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06665178.